Literature DB >> 24692791

Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study.

Agnes L F Chan1, Haw Yu Lee2, Chi-Hou Ho3, Thau-Ming Cham4, Shun Jin Lin4.   

Abstract

BACKGROUND: Adverse drug reactions (AADRs) are a leading cause of morbidity and mortality. In the United States, ADR-related morbidity and mortality costs have been estimated at US $330 billion to US $1130 billion annually.
OBJECTIVES: The aim of this study was to evaluate the incidence of ADRs in Taiwan, to identify the drug classes that are most commonly related to ADRs, and to determine the direct medical costs to hospitals associated with prolonged hospitalizations due to ADRs.
METHODS: In this prospective, descriptive, observational study, patients who experienced ADRs during their hospitalization at a Taiwan teaching hospital or who were admitted due to an ADR from January 1, 2002, through December 31, 2004, were included in the study. The patients were identified actively by clinical pharmacists and passively by physicians and nurses who reported ADRs. The World Health Organization (WWHO) definition of ADR severity was adopted, and degrees of probability for each ADR were determined using the Naranjo algorithm. The direct medical costs incurred to the hospital in the treatment of ADRs that prolonged hospitalization were calculated (ie, costs of emergency department [ED] visits, intensive care unit visits, extra days of hospitalization, monitoring and laboratory studies, pharmacist dispensing fees, physician fees, room charges, ED charges).
RESULTS: During the study period, 43 of the 142,295 hospitalized patients (00.03%)) were admitted because of an ADR. A total of 564 (00.40%)) of the hospitalized patients were verified to have ADRs. Three hundred eighteen of the patients (56.44%) with ADRs were male and the overall mean (SD) age was 66(2) years. The most common drug classes associated with the ADRs were antibiotics (219 patients [38.8% ]), analgesics (62 [11.0%]), and cardiovascular agents (56 [9.9%]). The systems most commonly involved in ADRs were cutaneous (296 patients [52.5%]), hematologic (61 [10.8%]), and cardiovascular (54 [9.66%]). The causes of the ADRs were anaphylactic (464 patients [82.3%]), drug overdose (78 [13.8%]), and drug-drug interactions (22 [3.9%]). Of the ADRs, 474 (884.0%) were idiosyncratic type B reactions (predictable). ADR-related costs, estimated at US $3489/ADR, were mostly due to prolonged length of stay. Based on the WHO definition, of the 564 ADRs, 330 (58.5%) and 40 (7.1%) were classified as moderate and severe, respectively. Two patients died of ADRs associated with allopurinol.
CONCLUSION: In this hospital, 0.40% of patients were identified as having ADRs that were associated with high direct costs, mostly due to extended hospitalizations.

Entities:  

Keywords:  adverse drug reactions; direct medical cost

Year:  2008        PMID: 24692791      PMCID: PMC3969903          DOI: 10.1016/j.curtheres.2008.04.005

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  22 in total

Review 1.  Counting the costs of drug-related adverse events.

Authors:  T J White; A Arakelian; J P Rho
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

2.  Development, implementation, and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital.

Authors:  B M Murphy; L C Frigo
Journal:  Hosp Pharm       Date:  1993-12

3.  Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands.

Authors:  Cornelis S van der Hooft; Miriam C J M Sturkenboom; Kees van Grootheest; Herre J Kingma; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Drugs and adverse drug reactions: how worried should we be?

Authors:  D W Bates
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

5.  Multidisciplinary program for detecting and evaluating adverse drug reactions.

Authors:  M R Keith; R A Bellanger-McCleery; J E Fuchs
Journal:  Am J Hosp Pharm       Date:  1989-09

6.  Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA).

Authors:  Graziano Onder; Claudio Pedone; Francesco Landi; Matteo Cesari; Cecilia Della Vedova; Roberto Bernabei; Giovanni Gambassi
Journal:  J Am Geriatr Soc       Date:  2002-12       Impact factor: 5.562

Review 7.  Life-threatening acute adverse cutaneous drug reactions.

Authors:  Ronni Wolf; Edith Orion; Batsheva Marcos; Hagit Matz
Journal:  Clin Dermatol       Date:  2005 Mar-Apr       Impact factor: 3.541

8.  Clinical and economic impact of adverse drug reactions in hospitalized patients.

Authors:  D C Suh; B S Woodall; S K Shin; E R Hermes-De Santis
Journal:  Ann Pharmacother       Date:  2000-12       Impact factor: 3.154

9.  Is age an independent risk factor of adverse drug reactions in hospitalized medical patients?

Authors:  P Carbonin; M Pahor; R Bernabei; A Sgadari
Journal:  J Am Geriatr Soc       Date:  1991-11       Impact factor: 5.562

10.  Computerized surveillance of adverse drug events in hospital patients.

Authors:  D C Classen; S L Pestotnik; R S Evans; J P Burke
Journal:  JAMA       Date:  1991-11-27       Impact factor: 56.272

View more
  7 in total

Review 1.  Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis.

Authors:  T J Oscanoa; F Lizaraso; Alfonso Carvajal
Journal:  Eur J Clin Pharmacol       Date:  2017-03-01       Impact factor: 2.953

Review 2.  How are the costs of drug-related morbidity measured?: a systematic literature review.

Authors:  Hanna Gyllensten; Anna K Jönsson; Clas Rehnberg; Anders Carlsten
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

Review 3.  The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.

Authors:  Patricia T Illing; Anthony W Purcell; James McCluskey
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 3.330

4.  Factors associated with adverse drug reaction occurrence and prognosis, and their economic impacts in older inpatients in Taiwan: a nested case-control study.

Authors:  Pei-Ju Liao; Chien-Tai Mao; Tun-Liang Chen; Shin-Tarng Deng; Kuang-Hung Hsu
Journal:  BMJ Open       Date:  2019-05-10       Impact factor: 2.692

5.  Prevalence and assessment of factors contributing to adverse drug reactions in wards of a tertiary care hospital, India.

Authors:  Demissew Berihun Haile; Wubeante Yenet Ayen; Pramil Tiwari
Journal:  Ethiop J Health Sci       Date:  2013-03

6.  Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China.

Authors:  Shi Qing-ping; Jiang Xiao-dong; Ding Feng; Liu Yan; Yu Mei-ling; Zhu Jin-xiu; Zhang Shu-qiang
Journal:  BMC Health Serv Res       Date:  2014-02-17       Impact factor: 2.655

7.  Assessment of Adverse Drug Reactions Based on Spontaneous Signals at Secondary Care Public Hospital.

Authors:  S Ponnusankar; M Tejaswini; M Chaitanya
Journal:  Indian J Pharm Sci       Date:  2015 Jul-Aug       Impact factor: 0.975

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.